Theorem Clinical Research

Evotec

Evotec partners to develop multiple sclerosis treatments

Tuesday, September 30, 2014 10:00 AM

Evotec, a German-based drug discovery alliance and development partnership company, has entered into three novel research projects for the treatment of multiple sclerosis (MS), supported by research funds from the German Federal Ministry of Education and Research (BMBF).

More... »


Evotec takes legal steps against Andromeda Biotech

Friday, September 19, 2014 01:26 PM

Evotec, a Germany-based drug discovery alliance and development partnership company, will take legal steps against Israel-based Andromeda Biotech to recover all Evotec claims and potential damages that result from recent incidents in relation to DiaPep277.

More... »


Evotec, CHDI Foundation extend ongoing Huntington's disease collaboration

Friday, September 12, 2014 01:00 PM

The CHDI Foundation, a U.S. privately-funded nonprofit biomedical research organization, has extended and restated its collaboration with Evotec, a drug discovery solutions company based in Germany, through 2017. The collaboration, which aims to find new treatments for Huntington's disease, an inherited neurodegenerative disorder, means CHDI will fund up to 52 full-time scientists at Evotec over the next three years.

More... »

Evotec acquires Euprotec to augment anti-infectives platform

Thursday, May 29, 2014 01:04 PM

Evotec has acquired Euprotec, a U.K.-based specialist CRO. With a comprehensive portfolio of assays and disease models, Euprotec supports anti-infective drug discovery and development programs through to late stage preclinical investigation and clinical proof-of-concept studies.

More... »

Evotec, Eternygen collaborate for novel metabolic disease therapy

Monday, May 12, 2014 12:19 PM

Evotec, a drug discovery alliance and development partnership company, and Eternygen, a Berlin-based, privately owned biopharmaceutical company, are collaborating to develop novel small molecule inhibitors against an Eternygen target to treat metabolic diseases using Evotec's technology platform and experience in drug discovery and preclinical development.

More... »

Evotec inks agreements with Debiopharm Group, Convergence

Monday, April 7, 2014 12:37 PM

Evotec, a drug discovery alliance and development partnership company, has formed a research collaboration and licensing deal with Debiopharm Group, a Swiss-based global biopharmaceutical group, to identify and develop novel compounds having the potential to treat multiple forms of solid tumors and leukemias with defined genetic alterations.

More... »

Evotec, Debiopharm Group to collaborate on new treatment for cancer

Thursday, April 3, 2014 10:55 AM

Evotec has formed a research collaboration and licensing deal with Debiopharm Group, a Swiss-based global biopharmaceutical group, to identify and develop novel compounds having the potential to treat multiple forms of solid tumors and leukemia’s with defined genetic alterations. Discovery and preclinical development efforts will be driven by Evotec, while Debiopharm will manage clinical development. Evotec will receive R&D funding and high double-digit total payments triggered by clinical, regulatory and commercial milestones, plus royalties on sales of resulting commercial products.

More... »

Evotec collaborates with Leukemia & Lymphoma Society

Wednesday, November 6, 2013 12:59 PM

Evotec has entered into an integrated research collaboration with the Leukemia & Lymphoma Society (LLS). Evotec will support one of LLS's Screen-to-Lead Programs (SLP).

More... »

Evotec, AstraZeneca enters alliance for kidney disease

Thursday, October 24, 2013 12:12 PM

Evotec has signed an agreement with AstraZeneca in kidney diseases. Initial focus of the alliance will be exploring compounds and targets with novel mechanisms that have disease-modifying potential for the treatment of chronic kidney disease.

More... »

Evotec receives $5.4 million milestone payment from Boehringer Ingelheim

Monday, October 21, 2013 11:52 AM

Evotec’s research alliance with Boehringer Ingelheim has reached a milestone in September triggering revenues of $5.4 million to Evotec. The milestone was for the transition of an oncology molecule into pre-clinical development.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs